Andrew Cheng Akero Therapeutics, Inc. (AKRO) insider trading activity

Andrew Cheng is President and CEO of Akero Therapeutics, Inc.. Currently has a direct ownership of 490,757 shares of AKRO, which is worth approximately $21.9 Million. The most recent transaction as insider was on Sep 13, 2022, when has been sold 60,000 shares (Common Stock) at a price of $0.62 per share, resulting in proceeds of $37,200. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 491K

11.81% 3M change

18.94% 12M change

Total Value Held $21.9 Million

Andrew Cheng Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 13 2022	BUY Exercise of conversion of derivative security	$37,200 $0.62 p/Share	60,000 Added 13.95%	370,148 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$9,251 $8.03 p/Share	1,152 Added 0.37%	310,148 Common Stock
Mar 01 2022	SELL Open market or private sale	$175,900 $17.59 p/Share	10,000 Reduced 3.13%	308,996 Common Stock
Mar 01 2022	BUY Exercise of conversion of derivative security	$6,200 $0.62 p/Share	10,000 Added 3.04%	318,996 Common Stock
Feb 01 2022	SELL Open market or private sale	$175,600 $17.56 p/Share	10,000 Reduced 3.13%	308,996 Common Stock
Feb 01 2022	BUY Exercise of conversion of derivative security	$6,200 $0.62 p/Share	10,000 Added 3.04%	318,996 Common Stock
Jan 10 2022	BUY Exercise of conversion of derivative security	$6,200 $0.62 p/Share	10,000 Added 3.13%	308,996 Common Stock
Jan 03 2022	BUY Exercise of conversion of derivative security	$32,860 $0.62 p/Share	53,000 Added 14.64%	308,996 Common Stock
Dec 02 2021	SELL Open market or private sale	$353,150 $20.18 p/Share	17,500 Reduced 6.4%	255,996 Common Stock
Nov 02 2021	SELL Open market or private sale	$394,975 $22.57 p/Share	17,500 Reduced 6.01%	273,496 Common Stock
Oct 04 2021	SELL Open market or private sale	$376,950 $21.54 p/Share	17,500 Reduced 5.67%	290,996 Common Stock
Sep 02 2021	SELL Open market or private sale	$418,075 $23.89 p/Share	17,500 Reduced 5.37%	308,496 Common Stock
Aug 03 2021	SELL Open market or private sale	$370,125 $21.15 p/Share	17,500 Reduced 5.09%	325,996 Common Stock
Jul 02 2021	SELL Open market or private sale	$433,650 $24.78 p/Share	17,500 Reduced 4.86%	342,489 Common Stock
Jan 10 2021	SELL Open market or private sale	$195,500 $19.55 p/Share	10,000 Reduced 3.24%	298,996 Common Stock
Jan 07 2021	BUY Exercise of conversion of derivative security	$12,400 $0.62 p/Share	20,000 Added 5.22%	362,989 Common Stock
Dec 31 2020	SELL Bona fide gift	-	3,000 Reduced 0.83%	359,989 Common Stock
Dec 28 2020	BUY Exercise of conversion of derivative security	$4,638 $0.62 p/Share	7,480 Added 2.13%	342,989 Common Stock
Dec 21 2020	BUY Exercise of conversion of derivative security	$6,510 $0.62 p/Share	10,500 Added 3.03%	335,509 Common Stock
Dec 15 2020	SELL Bona fide gift	-	2,500 Reduced 0.76%	325,009 Common Stock
Dec 11 2020	SELL Bona fide gift	-	50 Reduced 0.02%	327,509 Common Stock
Jun 30 2020	BUY Grant, award, or other acquisition	$21,252 $17.07 p/Share	1,245 Added 0.38%	327,559 Common Stock

Also insider at

VERA

Vera Therapeutics, Inc. Healthcare

ABUS

Arbutus Biopharma Corp Healthcare

Director

Andrew Cheng

President and CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account